Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/535,503external-prioritypatent/US4501890A/en
Priority claimed from US06/535,474external-prioritypatent/US4521421A/en
Priority claimed from US06/575,126external-prioritypatent/US4528290A/en
Priority claimed from FI843282Aexternal-prioritypatent/FI78091C/en
Application filed by Lilly Co ElifiledCriticalLilly Co Eli
Publication of FI882658ApublicationCriticalpatent/FI882658A/en
Publication of FI882658A0publicationCriticalpatent/FI882658A0/en
Application grantedgrantedCritical
Publication of FI80679BpublicationCriticalpatent/FI80679B/en
Publication of FI80679CpublicationCriticalpatent/FI80679C/en
FI882658A1983-09-261988-06-06
TRANS- () -1- (ALKYL ELLER ALLYL) -6-OXO-7-ALCOXYCARBONYLDEKAHYDROKINOLINER SOM AER ANVAENDBARA SOM MELLAN PRODUKTER VID FRAMSTAELLNING AV SOM DOPAMINAGONISTER ANVAENDBARA PYRIMIDO / 4,5-G.
FI80679C
(en)
TRANS- () -1- (ALKYL ELLER ALLYL) -6-OXO-7-ALCOXYCARBONYLDEKAHYDROKINOLINER SOM AER ANVAENDBARA SOM MELLAN PRODUKTER VID FRAMSTAELLNING AV SOM DOPAMINAGONISTER ANVAENDBARA PYRIMIDO / 4,5-G.
ANSLUTNINGSKLAEMMA FOER AVISOLERINGSFRI ANSLUTNING AV ELLEDNINGAR VID TELEKOMMUNIKATIONSANORDNINGARS, SPECIELLT VID SAMTALSFOERMEDLINGSANORDNINGARS FOERDELARE.